Bacterial Vaginosis

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Bacterial vaginosis (BV) is the single most common cause of abnormal vaginal discharge in reproductive-age women. If you have noticed a thin, greyish discharge and a fishy smell that gets stronger after sex, you are not imagining it, you did not do anything wrong, and you are very far from alone. BV is extraordinarily common, it is treatable, and the most important thing to understand up front is what it is not.

Let us clear away three myths immediately, because they cause a lot of unnecessary shame:

BV is not a sexually transmitted infection (STI) in the classic sense. It is strongly linked to sexual activity, but you do not "catch" BV from a partner the way you catch chlamydia or gonorrhea. People who have never had sex can develop it, although it is far more common in people who are sexually active.
BV is not caused by being unclean. This is the opposite of the truth. Over-washing, douching, and scented "feminine hygiene" products are among the things that cause or worsen BV by stripping out the protective bacteria your vagina needs. The vagina is self-cleaning. Scrubbing it makes BV more likely, not less.
BV is not a moral failing or a sign that something is wrong with you as a person. It is a shift in the balance of the bacteria that normally live in the vagina, in the same way that the bacteria on your skin or in your gut can shift.

What BV actually is, in one sentence: a dysbiosis — a change in the community of microbes living in the vagina. Specifically, the protective Lactobacillus bacteria that normally dominate and keep the vagina acidic are lost, and a mix of other bacteria (especially anaerobes such as Gardnerella vaginalis) overgrow in their place. The acidic environment that usually protects you breaks down, the pH rises, and the characteristic discharge and odor appear.

This page walks through what BV is, how to tell it apart from a yeast infection or trichomoniasis (which are often confused), why it genuinely matters to your health beyond the annoyance, how it is properly diagnosed and treated, why it comes back so often (and what is being done about that), and an honest accounting of what the evidence says about probiotics and home remedies.

2. Epidemiology

BV is common on a scale that surprises most people. A 2019 systematic review and meta-analysis estimated that roughly 23–29% of reproductive-age women worldwide have BV at any given time, with hundreds of millions of cases globally and an enormous combined healthcare cost (Peebles et al., 2019). In large U.S. population surveys, the prevalence among women aged 14–49 has been measured at around 29%, which is roughly one in three.

A striking feature of those numbers is that a large fraction of people with BV have no symptoms at all. Many cases are found only when a clinician examines a sample for another reason. This matters for two reasons: first, it means BV is even more common than the symptomatic cases suggest; and second, it complicates the question of whom to treat, because treating people without symptoms is generally not recommended outside of pregnancy.

BV is more frequently identified in some groups than others, including Black and Hispanic women in U.S. data, women who douche, women with new or multiple sexual partners, and women who have sex with women. These associations reflect a mix of behavioral and biological factors and should never be read as anyone's fault.

3. Pathophysiology

To understand BV, picture the healthy vagina as a well-tended garden dominated by one helpful species. In most reproductive-age women, the vaginal microbiome is dominated by Lactobacillus species, which do something quietly remarkable: they ferment glycogen (a sugar shed by the vaginal lining under the influence of estrogen) into lactic acid. That lactic acid keeps the vaginal pH low — normally below 4.5, about as acidic as a tomato. Some Lactobacillus strains also produce hydrogen peroxide and other compounds that suppress the growth of less friendly bacteria. This acidic, Lactobacillus-rich state is the body's frontline defense.

In BV, this protective state collapses. The Lactobacillus population crashes, the pH climbs above 4.5, and a dense, diverse community of anaerobic bacteria moves in. Gardnerella vaginalis is the species most associated with BV, but it is not acting alone — Atopobium (Fannyhessea) vaginae, Prevotella, Mobiluncus, and several others are part of the shift. Landmark molecular studies using DNA sequencing rather than culture revealed just how many previously unrecognized bacteria are involved (Fredricks et al., 2005).

A key insight from the last two decades is the role of the biofilm. The BV-associated bacteria, led by Gardnerella, do not just float freely — they build a sticky, structured film that adheres to the vaginal wall (Swidsinski et al., 2005). This biofilm shields the bacteria from antibiotics and from the body's own defenses, which is a major reason BV is so hard to cure permanently. When you finish a course of treatment, dormant biofilm can reseed the infection. An updated conceptual model frames BV as a polymicrobial process in which an initial colonizer establishes the biofilm and other species join in a coordinated succession (Muzny et al., 2019).

The smell people notice comes from chemistry: the anaerobes produce amines (such as putrescine and cadaverine). These are volatile and become especially noticeable in the presence of an alkaline fluid — which is exactly why the fishy odor flares after sex (semen is alkaline) or around menstruation.

4. Etiology and Risk Factors

BV is not caused by a single germ you pick up; it is the end result of the protective microbiome being disrupted. Several things make that disruption more likely:

Douching — this is one of the clearest and most controllable risk factors. Douching flushes out the protective Lactobacillus and raises the pH, doing precisely what you do not want. If you take one practical thing from this page: stop douching. There is no health benefit to it, and major medical bodies recommend against it.
Scented and "feminine hygiene" products — scented washes, wipes, sprays, deodorants, and bubble baths can irritate and disrupt the vaginal environment. Plain water on the external vulva is all that is needed; nothing should go inside.
New or multiple sexual partners, and a new male or female partner. BV behaves epidemiologically a bit like an STI even though it is not classified as one. Sexual exchange of bacteria appears to seed or reseed the dysbiosis.
Not using condoms. Condom use is associated with lower BV rates, likely because semen is alkaline and shifts the pH.
Sex between women shows high concordance of vaginal microbiomes between partners.
Menstruation (blood is alkaline) and copper IUDs (in some studies) can be associated with BV.
Smoking is consistently linked to a less Lactobacillus-dominant microbiome.

And a crucial honest point: in many people there is no identifiable cause at all. You can do everything "right" — never douche, use condoms, have one partner — and still get recurrent BV. That is not a personal failure. The microbiome is genuinely complex, and we do not yet fully understand why some people's protective Lactobacillus is so easily displaced.

5. Clinical Presentation

The classic symptoms of BV are:

A thin, greyish-white discharge that often coats the vaginal walls.
A "fishy" odor, classically stronger after sex or around your period.
Usually little or no itching, burning, redness, or swelling. This is an important distinguishing feature — BV is generally not an inflamed, intensely itchy condition.

Many people with BV have no symptoms whatsoever. When symptoms are present, the absence of significant itch and irritation is one of the biggest clues that you are dealing with BV rather than a yeast infection.

Telling BV apart from yeast and trichomoniasis

This is the single most useful thing on this page, because these three conditions are constantly confused — and the treatments are completely different. Studies repeatedly show that self-diagnosis is wrong a large share of the time: many people who buy over-the-counter yeast treatments do not actually have yeast. Here is how they differ:

Bacterial vaginosis (BV). Discharge is thin and grey-white. The hallmark is a fishy odor, worse after sex. The vaginal pH is high (above 4.5). There is usually no significant itching or inflammation. BV is a bacterial imbalance, not an STI, and a male partner does not normally need treatment (though, as discussed below, that picture is changing for recurrent cases).
Yeast infection (vulvovaginal candidiasis). Discharge is thick, white, and clumpy — often compared to cottage cheese — and typically has no strong odor. The defining symptoms are itching, burning, redness, and swelling of the vulva. The vaginal pH stays normal (below 4.5). It is caused by an overgrowth of Candida yeast, not bacteria, and is treated with antifungals, not antibiotics. (See the companion page on Yeast Infections.)
Trichomoniasis ("trich"). This one is a sexually transmitted infection, caused by a parasite (Trichomonas vaginalis). Discharge is often frothy, yellow-green, sometimes with odor, and may come with itching and irritation; the vaginal pH is high, like BV. Because it is an STI, the partner must be treated too, or you will simply pass it back and forth.

The practical takeaway: because BV and trich both raise the pH and can both involve discharge and odor, and because yeast can overlap with itching from other causes, guessing is unreliable. If your symptoms are new, recurrent, or you are pregnant, the right move is to get tested rather than self-treat from the pharmacy shelf. Testing is quick, and it stops you from treating the wrong thing — or missing a true STI like trich.

6. Diagnosis

BV can be diagnosed accurately and inexpensively. The point of testing is not bureaucracy — it is that the three conditions above look similar and are treated differently, so a real diagnosis spares you from chasing the wrong problem.

Amsel clinical criteria

In a clinic, the classic bedside method is the Amsel criteria (Amsel et al., 1983). A diagnosis of BV is made when at least three of four features are present:

Thin, homogeneous grey-white discharge.
Vaginal pH above 4.5 (checked with a simple pH strip).
A positive "whiff test" — adding a drop of potassium hydroxide (KOH) releases a fishy amine odor.
"Clue cells" on microscopy — vaginal cells so coated in bacteria that their borders look stippled and blurred.

Gram stain and the Nugent score

The laboratory reference standard is the Nugent score, a standardized way of reading a Gram-stained slide that counts the balance of Lactobacillus versus BV-associated bacterial morphotypes and produces a 0–10 score (Nugent et al., 1991). A score of 7–10 indicates BV. Standardizing the reading dramatically improved how reproducibly BV could be diagnosed across laboratories.

Modern molecular tests

Newer molecular (DNA/RNA-based) tests can detect and quantify BV-associated organisms from a vaginal swab, sometimes alongside yeast and trichomonas in a single panel. These are convenient and highly sensitive, and some can be done from a self-collected swab. They are more expensive than a pH strip and a microscope slide, and a positive result still has to be interpreted alongside symptoms — finding some Gardnerella does not always mean clinically significant BV.

The honest bottom line on diagnosis: get tested rather than guess. Self-diagnosis frequently misroutes people into buying yeast products that will not help, leaving a true BV (or a real STI) untreated.

7. Treatment

The good news is that first-line treatment is simple, cheap, and effective in the short term. The frustrating news, which we will be honest about, is that it comes back a lot.

First-line antibiotics

Per the 2021 U.S. CDC sexually transmitted infections treatment guidelines (Workowski et al., 2021), the recommended regimens are:

Oral metronidazole, 500 mg twice daily for 7 days; or
Vaginal metronidazole gel (0.75%), once daily for 5 days; or
Vaginal clindamycin cream (2%), once daily at bedtime for 7 days.

Oral and vaginal routes work about equally well, so the choice often comes down to side effects and preference. Metronidazole can cause nausea and a metallic taste; the long-standing advice to avoid alcohol with it is now considered largely unnecessary by many experts, though some people still prefer to skip alcohol during treatment. Clindamycin cream is oil-based and can weaken latex condoms and diaphragms during use. Most people clear their symptoms within a week of finishing the course.

Important caveat: over-the-counter products are not a substitute. Pharmacy "yeast" treatments do nothing for BV, and BV antibiotics generally require a prescription.

The recurrence problem — you are not failing

Here is the part nobody warns people about loudly enough: BV comes back for more than half of people within a year. A landmark study tracking women after a standard course of oral metronidazole found a recurrence rate of around 58% at 12 months (Bradshaw et al., 2006). If your BV has returned again and again, that is not because you did something wrong or because the treatment "failed you" personally — it is a known, biology-driven limitation of how we currently treat BV. The biofilm that protects the bacteria is a big reason a course of antibiotics often suppresses rather than eradicates the problem.

This frustration is real and validated. Recurrent BV can affect your sex life, your confidence, and your sense of control over your own body. You deserve a clinician who takes it seriously rather than just handing you the same prescription each time.

Approaches for recurrent BV

Longer suppressive regimens. For frequent recurrences, guidelines support a longer maintenance approach — for example, vaginal metronidazole gel twice weekly for several months after an initial cure — to keep BV suppressed while the microbiome has a chance to stabilize.
Treating male partners (a genuine shift). For decades, treating male partners was thought not to help, and standard guidelines advised against it. That changed with a 2025 randomized trial (the partner-treatment trial, reported by Vodstrcil and colleagues in 2025): in couples where the woman had recurrent BV and a regular male partner, treating the male partner with oral plus topical antibiotics, alongside treating the woman, significantly reduced recurrence compared with treating the woman alone. The trial was actually stopped early because the benefit was clear. This supports the long-suspected idea that, at least for some couples, partner reinfection plays a role — and it gives people with recurrent BV a real new option to discuss with their clinician.
Boric acid as an adjunct. Intravaginal boric acid capsules are sometimes used, often after or alongside antibiotics, to help disrupt biofilm and lower the pH, particularly in recurrent or resistant cases. Boric acid is reasonably supported as an adjunct in this setting. It must only be used vaginally and never swallowed — boric acid is toxic if taken by mouth and must be kept away from children and pets.

Probiotics and live biotherapeutics — an honest read

The idea is intuitive and appealing: if BV is loss of Lactobacillus, why not put Lactobacillus back? The honest answer is that the evidence is mixed and promising rather than definitive, and you should be wary of products marketed as a guaranteed BV cure.

Most over-the-counter oral probiotic capsules contain gut strains that have not been shown to reliably colonize the vagina, and the trial evidence for them is inconsistent. The more scientifically serious work is on live biotherapeutic products — carefully chosen vaginal Lactobacillus strains delivered after antibiotics to help re-establish a protective community. The best-known example, LACTIN-V (a Lactobacillus crispatus product), was tested in a rigorous randomized trial and reduced BV recurrence compared with placebo when used after metronidazole (Cohen et al., 2020). That is a genuinely encouraging result, but it is one product in trials, not a finished, widely available cure. We should neither dismiss probiotics nor oversell them: the field is moving, and "promising but not yet definitive" is the accurate summary.

What does not work — and can do harm

Inserting yogurt into the vagina is not evidence-based; food-grade yogurt is not a controlled vaginal Lactobacillus therapy, and it can introduce its own problems.
Inserting garlic cloves is a popular internet remedy with no good evidence behind it and a real risk of irritation and even foreign-body problems. Do not do it.
Douching — including with vinegar — is actively harmful for BV. It is a cause, not a cure. Do not douche.

8. Complications — Why BV Matters Beyond the Annoyance

It would be easy to treat BV as a minor nuisance — an odor, an inconvenience. But the loss of the protective acidic barrier has real downstream consequences, and this is why getting it diagnosed and treated matters more than the symptoms alone suggest.

Increased susceptibility to STIs, including HIV. When the protective Lactobacillus is gone and the pH rises, the vaginal environment becomes more hospitable to other pathogens. BV is associated with higher risk of acquiring HIV, herpes, chlamydia, gonorrhea, and other infections, and with passing them on.
Pelvic inflammatory disease (PID). BV-associated organisms can ascend into the upper reproductive tract and contribute to PID, which can damage the fallopian tubes and is a recognized cause of infertility and ectopic pregnancy.
Pregnancy complications. BV in pregnancy is associated with an increased risk of preterm birth and low birth weight (Hillier et al., 1995), as well as late miscarriage and post-delivery infection. Pregnant patients who have symptoms of BV should be treated — talk to your obstetric provider. (The benefit of screening and treating asymptomatic pregnant women is less clear-cut and is an individual clinical decision.)
Post-procedure infection. BV raises the risk of infection after gynecologic surgery, including abortion and hysterectomy, which is why clinicians sometimes screen before these procedures.

None of this is meant to frighten you. The point is that BV is worth taking seriously and treating properly, not because it is dangerous in the immediate moment, but because the protective vaginal environment it disrupts is doing more for your health than most people realize.

9. Prognosis

For an individual episode, the outlook is good: first-line antibiotics resolve symptoms in the large majority of people within a week or two. The challenge is durability. As noted above, more than half of people see BV return within a year, and a subset live with a frustrating cycle of clearing and recurrence.

The trajectory is genuinely improving. Maintenance regimens, biofilm-disrupting adjuncts such as boric acid, the new evidence for partner treatment in recurrent cases, and live biotherapeutics in trials together mean that someone with stubborn recurrent BV today has more real options than they did a decade ago. If you are in that cycle, it is worth seeking out a clinician who is up to date on these approaches rather than accepting that "it just keeps coming back" as the final word.

10. Prevention

You cannot control everything about your vaginal microbiome — and it is important to say that plainly, so that recurrence does not feel like a personal failure. But there are concrete, evidence-aligned steps that genuinely tilt the odds in your favor:

Do not douche. This is the most important single thing. Douching offers no benefit and directly disrupts the protective bacteria.
Skip scented products inside or around the vagina — no scented washes, wipes, sprays, deodorants, or bubble baths. Plain warm water on the external vulva is enough.
Use condoms. Consistent condom use is associated with lower BV rates and also protects against the STIs that BV makes you more vulnerable to.
Be mindful of new partners. A new sexual partner is a recognized trigger; this is information, not blame.
Do not smoke — smoking is linked to a less protective vaginal microbiome.
Treat recurrent BV with a plan, not just a one-off prescription — ask your clinician about maintenance regimens, partner treatment where appropriate, and emerging Lactobacillus-based options.

And the honest limit: even doing all of this, some people will still get recurrent BV. The biology is not fully understood, and that is the medical system's gap to close, not yours.

11. Recent Research and Advances

BV is one of the most actively researched areas in women's health, in large part because the recurrence problem has remained unsolved for so long. Several lines of work are reshaping how the condition is understood and treated:

Rethinking BV as sexually shared. The 2025 partner-treatment trial (Vodstrcil et al., 2025) is the most consequential clinical result in years. By showing that treating regular male partners reduced recurrence in women with recurrent BV, it reopened the long-debated question of whether BV is, at least in part, sexually transmitted — and it may change treatment guidelines for couples affected by recurrent BV.
Microbiome science. DNA-sequencing studies have mapped the vaginal microbiome in detail, defining the "community state types" that range from protective Lactobacillus-dominant states to the diverse, anaerobe-rich state of BV (van de Wijgert et al., 2014). This work underpins the search for why some people's protective community is so fragile.
Biofilm-targeted approaches. Because the Gardnerella biofilm shields bacteria from antibiotics, researchers are testing agents and strategies aimed specifically at disrupting it — an avenue that could finally lower recurrence.
Live biotherapeutics. Following the LACTIN-V trial (Cohen et al., 2020), defined vaginal Lactobacillus crispatus products are being refined and studied as a way to durably re-seed a protective microbiome after antibiotics. These are real clinical products in trials, distinct from generic over-the-counter probiotics.
Better diagnostics. Molecular and point-of-care tests, including self-collected sampling, aim to make accurate diagnosis faster and more accessible, reducing reliance on guesswork and unhelpful over-the-counter self-treatment.

The overarching theme is encouraging: after decades in which BV was a frustrating cycle with one default treatment, the field is moving toward understanding it as a microbiome and biofilm problem — and treating it accordingly.

12. References & Research

Historical Background

The modern story of bacterial vaginosis begins in 1955, when Herman Gardner and Charles Dukes described an organism they called Haemophilus vaginalis — later renamed Gardnerella vaginalis in Gardner's honor — as the agent of what they then termed "nonspecific vaginitis" (Gardner & Dukes, 1955). For decades the condition resisted a precise definition. That changed with two methodological advances: the Amsel clinical criteria in 1983 (Amsel et al., 1983), which gave clinicians a reproducible bedside diagnosis, and the standardized Nugent Gram-stain score in 1991 (Nugent et al., 1991), which gave laboratories a reliable reference standard. The molecular and microbiome era then transformed the picture: DNA-sequencing studies revealed that BV involves a whole community of previously uncultured bacteria (Fredricks et al., 2005), and the recognition of the adherent Gardnerella biofilm (Swidsinski et al., 2005) explained why the condition is so hard to cure and so prone to recurrence. The most recent landmark is the 2025 male-partner treatment trial (Vodstrcil et al., 2025), which provided strong evidence that treating regular male partners can reduce recurrence — reframing how BV may be managed in affected couples.

Key Research Papers

Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. New England Journal of Medicine. 2025;392(10):947–957.
Cohen CR, Wierzbicki MR, French AL, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. New England Journal of Medicine. 2020;382(20):1906–1915.
Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187.
Muzny CA, Taylor CM, Swords WE, et al. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. The Journal of Infectious Diseases. 2019;220(9):1399–1405.
Peebles K, Velloza J, Balkus JE, et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sexually Transmitted Diseases. 2019;46(5):304–311.
van de Wijgert JHHM, Borgdorff H, Verhelst R, et al. The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization? PLoS ONE. 2014;9(8):e105998.
Bradshaw CS, Morton AN, Hocking J, et al. High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with Recurrence. The Journal of Infectious Diseases. 2006;193(11):1478–1486.
Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent Biofilms in Bacterial Vaginosis. Obstetrics & Gynecology. 2005;106(5 Pt 1):1013–1023.
Fredricks DN, Fiedler TL, Marrazzo JM. Molecular Identification of Bacteria Associated with Bacterial Vaginosis. New England Journal of Medicine. 2005;353(18):1899–1911.
Sobel JD. Vaginitis. New England Journal of Medicine. 1997;337(26):1896–1903.
Hillier SL, Nugent RP, Eschenbach DA, et al. Association between Bacterial Vaginosis and Preterm Delivery of a Low-Birth-Weight Infant. New England Journal of Medicine. 1995;333(26):1737–1742.
Nugent RP, Krohn MA, Hillier SL. Reliability of Diagnosing Bacterial Vaginosis Is Improved by a Standardized Method of Gram Stain Interpretation. Journal of Clinical Microbiology. 1991;29(2):297–301.
Amsel R, Totten PA, Spiegel CA, et al. Nonspecific Vaginitis: Diagnostic Criteria and Microbial and Epidemiologic Associations. The American Journal of Medicine. 1983;74(1):14–22.
Gardner HL, Dukes CD. Haemophilus Vaginalis Vaginitis: A Newly Defined Specific Infection Previously Classified "Nonspecific" Vaginitis. American Journal of Obstetrics and Gynecology. 1955;69(5):962–976.

Research Papers

Bacterial vaginosis is an actively evolving field. The PubMed searches below pull up-to-date, peer-reviewed literature on its microbiology, diagnosis, treatment, recurrence, and links to other conditions. Each opens in a new tab.

Connections

Back to Table of Contents